Tecan Group stock
Price history
+79.40% over the period1 year: from CHF 133.00 (November 20, 2025) to CHF 238.60 (November 20, 2026), +79.40%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | CHF 238.60 |
| October 30, 2026 | CHF 247.00 |
| September 30, 2026 | CHF 234.40 |
| August 31, 2026 | CHF 197.60 |
| July 31, 2026 | CHF 186.10 |
| June 30, 2026 | CHF 161.80 |
| May 29, 2026 | CHF 155.40 |
| April 30, 2026 | CHF 117.70 |
| March 31, 2026 | CHF 133.40 |
| February 27, 2026 | CHF 136.20 |
| January 30, 2026 | CHF 136.00 |
| December 30, 2025 | CHF 128.50 |
| November 28, 2025 | CHF 138.40 |
| November 20, 2025 | CHF 133.00 |
At a glance
The company
Provide laboratory instruments and automation solutions for biopharmaceuticals, clinical diagnostics, and forensics
Latest results
Quarter to June 30, 2026 · EPS CHF 0.99
TickerLandia's take on Tecan Group
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−14.17% from the 52-week high
Analysts · 8 analysts
Average targetCHF 222.73−6.65% vs. price
Buy 3 · Hold 5 · Sell 0 · Buy
TickerLandia Fingerprint: Tecan Group
Compared with similar companies: very strong momentum, very low profitability, and very low growth.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh63
How much it costs relative to what it produces.
Metric Value Position in group Price/sales 3.45 57 Forward P/E 30.4 69 EV/EBITDA 39.4 90 Price/book 2.69 37 Profitabilityvery low7
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 4.9% 4 Gross margin 34.1% 16 Net margin −13.4% 4 ROE −9.7% 4 ROA 1.5% 7 Earnings stabilitylow26
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 4.1% 34 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 18 Growthvery low9
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) −2.70% 13 Average revenue growth (3 years) −8.29% 1 Earnings growth (year over year) −29.80% 12 Financial strengthhigh71
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.19 74 Interest coverage 15.7 82 Current ratio 2.32 69 Net debt/EBITDAcounts in reverse: lower means more financial strength 0.52 58 Dividendhigh68
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 27 years 71 Dividend yield 1.2% 54 Payout ratio 60.6% 77 Market momentumvery strong96
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +19.42% 92 Relative strength (6 months) +51.20% 98 1-year return +79.40% 97 Distance from 200-day average +35.66% 99 Riskhigh68
How much the price swings.
Metric Value Position in group Beta (1 year) 0.87 60 Volatility (60 days) 39.7% 81 Maximum drawdown (12 months) 28.4% 64
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Tecan Group is pricier than similar companies
Tecan Group's Forward P/E: 30.4, +48% against the median of a group of 11 similar companies (20.6).
Compared with 11 similar companies
| Metric | Tecan Group | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 30.4 | High | |
| Operating margin | 4.9% | Low | |
| ROE | -9.7% | Low | |
| Debt/equity | 0.19 | Low | |
| Price/book | 2.69 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Tecan Group. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
CHF 427.53M
Latest quarter · Q2 2026
Net income
CHF 12.27M
Latest quarter · Q2 2026
Quarterly net margin
2.9%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- CHF 3B
- EPS
- -CHF 9.01
- Volume
- 48.91K
- Daily trading
- €18.69M
- Dividend yield
- 1.26%
- Last ex-dividend on April 17, 2026
How Tecan Group is changing
All resultsRevenue grew 3.8% a year on average over the last 5 years
Operating margin fell from 12.9% to 5.1%
Shares outstanding up 5.2% in 5 years
Returns
Tecan Group returns with dividends
CHF 1,000 invested in Tecan Group 5 years ago, on November 22, 2021, would be worth CHF 445 today with dividends reinvested: −55.47% in total, −14.95% per year. On price alone it would be CHF 416 (−58.36%).
| Period | Tecan Group | SMI | CHF 1,000 becomes |
|---|---|---|---|
| 1 month | −2.21% | +0.65% | CHF 978 |
| 6 months | +64.44% | +8.75% | CHF 1,644 |
| Year to date | +85.68% | +9.83% | CHF 1,857 |
| 1 year | +83.30% | +16.18% | CHF 1,833 |
| 3 years | −17.23% | +35.68% | CHF 828 |
| 5 years | −55.47% | +16.48% | CHF 445 |
| 10 years | +62.31% | +85.64% | CHF 1,623 |
Over the last 6 months it has done better than 88% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment
The chart in detail
Tecan Group: technical analysis
Tecan Group is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 59.9% below its all-time closing high (CHF 594.50, August 23, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 46
- Between 30 and 70
- vs 200-session average
- +35.66%
Support and resistance
Price areas where Tecan Group has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last priceCHF 238.60
- SupportCHF 235.90−1.13%2 touches, last on November 3, 2026
- SupportCHF 201.50−15.55%2 touches, last on September 1, 2026
- SupportCHF 183.53−23.08%3 touches, last on August 26, 2026
Volatility and risk
Over the last year it has moved roughly in line with the SMI.
- Beta (1 year) vs SMI
- 0.87
- Volatility (60 sessions, annualised)
- 39.7%
- Largest fall in the last year
- −28.45%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Tecan Group: seasonality
Average monthly price change over 32 years
Over the last 32 years, the strongest month for Tecan Group has been November: +3.96% on average, positive in 20 years out of 31. The weakest has been March: −0.68% on average, positive in 16 years out of 31.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.00% | +0.29% | 16 of 31 |
| February | +2.56% | +0.28% | 17 of 31 |
| March | −0.68% | +0.38% | 16 of 31 |
| April | +0.96% | +3.16% | 18 of 31 |
| May | +3.73% | +1.68% | 20 of 32 |
| June | +0.17% | +1.04% | 17 of 32 |
| July | +0.71% | +1.44% | 19 of 32 |
| August | +2.29% | +1.91% | 20 of 32 |
| September | +0.13% | +0.30% | 17 of 32 |
| October | −0.11% | +0.19% | 16 of 32 |
| November | +3.96% | +5.10% | 20 of 31 |
| December | +3.38% | +5.08% | 21 of 31 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Tecan Group and its competitors
Headquartered in Männedorf, Switzerland, the company was founded in 1980 and builds laboratory instruments for customers in biopharmaceutical, forensic and clinical diagnostics settings. Its Life Sciences Business covers liquid handling and automation systems, microplate readers and washers, laboratory software, consumables, sequencing reagents, and immunoassays and antibodies. The Partnering Business offers contract design and manufacturing through PARAMIT, while Tecan Labwerx provides an end-to-end automation solution.
- Headquarters
- Männedorf, Switzerland
- Employees
- 3,000
- Founded
- 1980
- Chief executive
- Monica Manotas
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Tecan GroupTECN | $3.58B | 4.9% | — | +64.44% |
| SCHOTT Pharma1SXP | $3.74B | 16.4% | 25.1 | +34.04% |
| Fielmann GroupFIE | $3.93B | 13.7% | 16.4 | −3.95% |
| Carl Zeiss MeditecAFX | $3.07B | 7.2% | 23.3 | +24.32% |
| OttobockOBCK | $2.68B | 18.7% | 19.0 | −31.33% |
| AddLifeALIF.B | $2.11B | 8.9% | 33.5 | +17.73% |
Same industry or related industries, similar size. Compare Tecan Group with its competitors · Full profile
